E-viri
Recenzirano
Odprti dostop
-
Caprioli, Chiara; Lussana, Federico; Salmoiraghi, Silvia; Cavagna, Roberta; Buklijas, Ksenija; Elidi, Lara; Zanghi', Pamela; Michelato, Anna; Delaini, Federica; Oldani, Elena; Intermesoli, Tamara; Grassi, Anna; Gianfaldoni, Giacomo; Mannelli, Francesco; Ferrero, Dario; Audisio, Ernesta; Terruzzi, Elisabetta; De Paoli, Lorella; Cattaneo, Chiara; Borlenghi, Erika; Cavattoni, Irene; Tajana, Monica; Scattolin, Anna Maria; Mattei, Daniele; Corradini, Paolo; Campiotti, Leonardo; Ciceri, Fabio; Bernardi, Massimo; Todisco, Elisabetta; Cortelezzi, Agostino; Falini, Brunangelo; Pavoni, Chiara; Bassan, Renato; Spinelli, Orietta; Rambaldi, Alessandro
Haematologica, 08/2020, Letnik: 106, Številka: 10Journal Article
Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these features, uncertainties remain to identify the secondary nature of some cases otherwise defined as de novo AML. To test whether a chromatin-spliceosome (CS) mutational signature might better inform the definition of the de novo AML group, we analyzed a prospective cohort of 413 newly diagnosed AML patients enrolled into a randomized clinical trial (NILG AML 02/06) and provided with accurate cytogenetic and molecular characterization. Among clinically defined de novo AML, 17.6% carried CS mutations (CS-AML) and showed clinical characteristics closer to sAML (older age, lower white blood cell counts and higher rate of multilineage dysplasia). Outcomes in this group were adverse, more similar to those of sAML as compared to de novo AML (overall survival, 30% in CS-AML and 17% in sAML vs 61% in de novo AML, P<0.0001; disease free survival, 26% in CS-AML and 22% in sAML vs 54% of de novo AML, P<0.001) and independently confirmed by multivariable analysis. Allogeneic transplant in first complete remission improved survival in both sAML and CS-AML patients. In conclusion, these findings highlight the clinical significance of identifying CS-AML for improved prognostic prediction and potential therapeutic implications. (NILG AML 02/06: ClinicalTrials.gov Identifier: NCT00495287).
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.